Scandion Oncology – Overcoming cancer drug resistance

Subscribe for TO2 warrants

More about resistance

Cancer drug resistance

Pipeline

Pipeline

Financial reports

Financial Reports

PRESS RELEASES

13 January 2025

Scandion Oncology announces final data from the CORIST trial and is ready to move into a randomized phase II Proof of Concept trial in Colorectal Cancer

Scandion Oncology, an innovative drug efflux pump inhibition company using biomodulation capability to revert drug resistance, announces final data from CORIST trial part 1, 2 and 3. In this phase I/II trial heavily pretreated patients with advanced colorectal cancer were treated with different doses of FOLFIRI (folinic acid, 5-FU and Irinotecan) in combination with different doses of SCO-101 given in either a 4-day or 6-day schedule. The recommended Phase II dose (RP2D) is 250mg of SCO-101 and the 4-day schedule is the one to be pursued in a randomized phase II Proof of Concept trial. In total 71 patients have received at least 1 dose of SCO-101 and are included in the safety analysis of SCO-101 and a total of 534 cycles have been given, which represents 20 patient years of treatment. Overall, the safety and tolerability profile has been very good. The maximal tolerated dose (MTD) for both the 4-day and the 6-day schedules have been defined. Furthermore, with a longer observation time no long-term safety issues have been found. With this update there is no new information on CORIST part 1 (N=18) which was finalized in April 2022. In CORIST part 2 (N=25), as previously reported, we have observed signs of clinical activity with a median Progression Free Survival (mPFS) of 2 months, median Overall Survival (mOS) of 10.4 months and Clinical Benefit Rate (CBR) of 42%. mPFS was increased from 1.80 to 2.04 months when the data was analyzed based on the bilirubin index (BI), which is a potential blood-based biomarker measuring the SCO-101 induced changes in bilirubin levels. We also found a highly statistically significant increase in mOS from 6.66 to 13.35 months based on the BI. In CORIST part 3 (N=28), two different dosing schedules were evaluated, the 4-day and the 6-day schedule. In both schedules, the MTD was found, and the RP2D of 250mg SCO 101 was established in the 4-day schedule. Importantly, in the 4-day schedule, amongst the 6 patients receiving the RP2D, two patients had a partial response (PR) with more than 30% tumor reduction and both these patients were treated until end of study (44-weeks) and have been offered continued treatment under a compassionate use program. The mPFS for all evaluable patients (N=24) in CORIST part 3 was found to be 3.76 months. Furthermore, we have identified UGT1A1 genotype as a potential biomarker with a mPFS of 7.04 months in patients […]

20 November 2024

Warrants of series TO 2 were exercised to approximately 2.0 per cent and Scandion Oncology receives approximately SEK 0.3 million

Today, on 20 November 2024, Scandion Oncology ("Scandion" or the "Company") announces the outcome of the exercise of warrants of series TO 2, which were issued in connection with the Company's rights issues of units during the second quarter of 2024. In total, 2,833,532 warrants of series TO 2 were exercised, corresponding to approximately 2.0 per cent of the total number of outstanding warrants of series TO 2, for subscription of 2,833,532 shares at an exercise price of SEK 0.12 per share. Scandion will thus receive approximately SEK 0.3 million before issuing costs. BackgrundScandion carried out a rights issue of units during the second quarter of 2024. Within the rights issue, a total of 143,416,179 warrants of series TO 2 were issued. One (1) warrant of series TO 2 entitles the holder to subscribe for one (1) new share in the Company. The exercise price for the warrants of series TO 2 was to be determined to seventy (70) per cent of the volume weighted average price of the Company’s share during the period from and including 16 October 2024 up to and including 29 October 2024, however not lower than the quota value of the share and not higher than 125 per cent of the subscription price in the rights issue. During the measurement period, the volume-weighted average price for the Company's share was approximately SEK 0.12, therefore the exercise price for the warrants of series TO 2 has been determined to SEK 0.12. Subscription of shares by exercise of warrants of series TO 2 takes place during the period from and including 4 November 2024 up to and including 18 November 2024. OutcomeIn total, 2,833,532 warrants of series TO 2 were exercised for subscription of 2,833,532 shares, meaning that approximately 2.0 per cent of all outstanding warrants of series TO 2 were exercised for subscription of shares. Scandion will thus receive approximately SEK 0.3 million before issuing costs. Exercised warrants of series TO 2 have been replaced with interim shares (IA), pending registration with the Danish Business Authority. The interim shares are expected to be converted to shares within approximately three weeks. Number of shares, share capital and dilutionThrough the exercise of warrants of series TO 2, the share capital in the Company will increase with DKK 208,264.6020 through the issuance of 2,833,532 new shares. This correspondence to a dilution effect of approximately 1.2 per cent of the […]

14 November 2024

Last day of trading in warrants of series TO 2 in Scandion Oncology is today, 14 November 2024

Scandion Oncology ("Scandion" or the "Company") announces that today, 14 November 2024, is the last day of trading in warrants of series TO 2. The exercise period for the warrants of series TO 2 runs up to and including 18 November 2024. One (1) warrant of series TO 2 entitles the holder to subscribe for one (1) new share in the Company. The exercise price is SEK 0.12 per share. Note that warrants of series TO 2 not sold by today, 14 November 2024, or used to subscribe for shares no later than on 18 November 2024, expire without value. Scandion carried out a rights issue of units during the second quarter of 2024. Within the rights issue, a total of 143,416,179 warrants of series TO 2 were issued. One (1) warrant of series TO 2 entitles the holder to subscribe for one (1) new share in the Company. The exercise price for the warrants of series TO 2 was to be determined to seventy (70) per cent of the volume weighted average price of the Company’s share during the period from and including 16 October 2024 up to and including 29 October 2024, however not lower than the quota value of the share and not higher than 125 per cent of the subscription price in the rights issue. During the measurement period, the volume-weighted average price for the Company's share was approximately SEK 0.12, therefore the exercise price for the warrants of series TO 2 has been determined to SEK 0.12. Subscription of shares by exercise of warrants of series TO 2 takes place during the period from and including 4 November 2024 up to and including 18 November 2024. If all the warrants of series TO 2 are exercised, the Company will receive approximately SEK 17,2 million before issue costs. For the warrants to not expire without value, it is required that the holder actively subscribes for new shares no later than on 18 November 2024 or sell the warrants no later than today, on 14 November 2024. Please observe that certain nominees might close their subscription earlier than on 18 November 2024. If all warrants of series TO 2 are exercised the share capital will increase with DKK 10,541,089.15650 through the issuance of 143,416,179 new shares. This correspondence to a dilution effect of approximately 38,2 per cent of the number of shares and number of votes. Full […]

All Press Releases

UPCOMING EVENTS

Year-end report 2024

Annual Report 2024

Annual General Meeting

View all upcoming events

Learn more about our unique first-in-class lead compound SCO-101

Watch the interview here: Part 1 / Part 2 / Part 3

Read more about SCO-101

Annual General Meeting

Scandion Oncology Annual General Meeting on May 6 at 14.00

Read more

LATEST PRESENTATIONS

KOL interview on CORIST – Professor Josep Tabernero, MD, PhD

Read more about the presentation here.

R&D Update May 15

Watch the R&D Update from May 15th

BioStock interview w. Francois Martelet

Our clinical study and partnering strategy are jointly progressing.

View all presentations

A great place to work

For talented, ambitious individuals who share our passion for science and drug development, we offer an exciting work environment, along with the opportunity to make a difference for the many cancer patients in need for novel treatments

Read more